Chiasma, Inc. announced a management transition intended to further strengthen the Company's leadership team ahead of the anticipated commercial availability of Mycapssa®. As part of the transition, the Company has appointed Raj Kannan as Chief Executive Officer. As of the Effective Date, Mark J. Fitzpatrick, the Company's current Chief Executive Officer, will continue to serve as the Company's President and principal financial officer and will resign from the Board.

Mr. Kannan will also join Chiasma's Board of Directors. The management transition is expected to be effective no later than June 17, 2019. Prior to joining Chiasma, Mr. Kannan served as Chief Commercial Officer at Kiniksa Pharmaceuticals since July 2018.